These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 31261222)

  • 21. Successful dupilumab treatment for ichthyotic and atopic features of Netherton syndrome.
    Murase C; Takeichi T; Taki T; Yoshikawa T; Suzuki A; Ogi T; Suga Y; Akiyama M
    J Dermatol Sci; 2021 May; 102(2):126-129. PubMed ID: 33773888
    [No Abstract]   [Full Text] [Related]  

  • 22. Acute onset of psoriasis in a patient with atopic dermatitis treated with dupilumab.
    Ferrucci S; Tavecchio S; Berti E; Angileri L
    Clin Exp Dermatol; 2020 Jul; 45(5):625-626. PubMed ID: 32112580
    [No Abstract]   [Full Text] [Related]  

  • 23. Oral Upadacitinib Beats Subcutaneous Dupilumab for Atopic Dermatitis.
    Slomski A
    JAMA; 2021 Oct; 326(13):1246. PubMed ID: 34609462
    [No Abstract]   [Full Text] [Related]  

  • 24. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials.
    Blauvelt A; Rosmarin D; Bieber T; Simpson EL; Bagel J; Worm M; Deleuran M; Katoh N; Kawashima M; Shumel B; Chen Z; Rossi AB; Hultsch T; Ardeleanu M
    Br J Dermatol; 2019 Jul; 181(1):196-197. PubMed ID: 30719707
    [No Abstract]   [Full Text] [Related]  

  • 25. Simultaneous effectiveness of dupilumab in atopic dermatitis and alopecia areata in two patients.
    Ludriksone L; Elsner P; Schliemann S
    J Dtsch Dermatol Ges; 2019 Dec; 17(12):1278-1280. PubMed ID: 31829527
    [No Abstract]   [Full Text] [Related]  

  • 26. Successful dupilumab therapy for atopic dermatitis in a patient with X-linked agammaglobulinaemia.
    Fujishima C; Munemoto S; Hioki C; Sasaki H; Yoshida H; Yamamoto T; Kudo H
    Eur J Dermatol; 2022 May; 32(3):416-417. PubMed ID: 36065552
    [No Abstract]   [Full Text] [Related]  

  • 27. [Psoriasis in dupilumab-treated atopic dermatitis].
    Senner S; Eicher L; Aszodi N; Prinz JC; French LE; Wollenberg A
    Hautarzt; 2020 May; 71(5):383-386. PubMed ID: 32179945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dupilumab therapy in a patient with atopic dermatitis and severe atopic keratoconjunctivitis.
    Gkalpakiotis S; Arenberger P; Skalicka P; Arenbergerova M
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):e281-e283. PubMed ID: 32031716
    [No Abstract]   [Full Text] [Related]  

  • 29. Real-world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study.
    Uchida H; Kamata M; Mizukawa I; Watanabe A; Agematsu A; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    Br J Dermatol; 2019 Nov; 181(5):1083-1085. PubMed ID: 31127860
    [No Abstract]   [Full Text] [Related]  

  • 30. Management Recommendations for Dupilumab Partial and Non-durable Responders in Atopic Dermatitis.
    Hendricks AJ; Lio PA; Shi VY
    Am J Clin Dermatol; 2019 Aug; 20(4):565-569. PubMed ID: 30919315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A rare presentation of herpes simplex virus encephalitis occurring in a pediatric patient on dupilumab for atopic dermatitis.
    Rao M; Grove D; Haggstrom A
    Pediatr Dermatol; 2022 Mar; 39(2):288-290. PubMed ID: 35243667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic.
    Hansel K; Patruno C; Antonelli E; Dal Bello G; Napolitano M; Fabbrocini G; Grieco T; Pellacani G; Fargnoli MC; Esposito M; Piras V; Zucca M; Girolomoni G; Stingeni L
    Clin Exp Dermatol; 2022 Jan; 47(1):165-167. PubMed ID: 34309892
    [No Abstract]   [Full Text] [Related]  

  • 33. Ulcerative colitis during dupilumab therapy in a patient with atopic dermatitis.
    Seishima M; Sasaki M; Hachiken H; Furukawa T; Yagi N; Sugie S
    J Dermatol; 2023 Dec; 50(12):e420-e421. PubMed ID: 37622193
    [No Abstract]   [Full Text] [Related]  

  • 34. A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab.
    D'Adamio S; Massaro A; Biocca S; Bianchi L; Talamonti M; Galluzzo M
    Clin Exp Dermatol; 2020 Aug; 45(6):809-810. PubMed ID: 32472943
    [No Abstract]   [Full Text] [Related]  

  • 35. Dupilumab Improves Atopic Dermatitis and Post-Inflammatory Hyperpigmentation in Patient With Skin of Color.
    Grayson C; Heath CR
    J Drugs Dermatol; 2020 Jul; 19(7):776-778. PubMed ID: 32726553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One-year real-world clinical effectiveness, safety, and laboratory safety of dupilumab in Japanese adult patients with atopic dermatitis: A single-center retrospective study.
    Uchida H; Kamata M; Kato A; Mizukawa I; Watanabe A; Agematsu A; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    J Am Acad Dermatol; 2021 Feb; 84(2):547-550. PubMed ID: 32479977
    [No Abstract]   [Full Text] [Related]  

  • 37. Long-term treatment of severe recalcitrant atopic dermatitis with omalizumab, an anti-immuno-globulin E.
    Quist SR; Ambach A; Göppner D; Quist J; Franke I; Bonnekoh B; Gollnick HP
    Acta Derm Venereol; 2013 Mar; 93(2):206-8. PubMed ID: 23042516
    [No Abstract]   [Full Text] [Related]  

  • 38. Herpes simplex virus encephalitis in atopic dermatitis patients and responses to dupilumab: A real association or a chance occurrence?
    Shi JQ; Dong XS; Zhang LL; Liu ZH
    Pediatr Dermatol; 2022 Sep; 39(5):848-849. PubMed ID: 36206220
    [No Abstract]   [Full Text] [Related]  

  • 39. Assessment of the Development of New Regional Dermatoses in Patients Treated for Atopic Dermatitis With Dupilumab.
    Zhu GA; Chen JK; Chiou A; Ko J; Honari G
    JAMA Dermatol; 2019 Jul; 155(7):850-852. PubMed ID: 31042259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A critical appraisal and implications of the new National Institute for Health and Care Excellence guideline on dupilumab for treating moderate-to-severe atopic eczema.
    Weidinger S; Apfelbacher C
    Br J Dermatol; 2019 Mar; 180(3):435-437. PubMed ID: 30821391
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.